Why Cardiovascular Supplements Fail: Mechanism Versus Clinical Proof

The eleven biological pathways every cardiovascular supplement claim borrows from — and the predictable reasons promising mechanisms fail to translate into clinical benefit.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not to replace medical care.

In brief: Almost every cardiovascular supplement claim targets one of eleven real biological pathways, and in each there is a predictable gap between what the biology suggests and what randomized trials in humans actually show. A biological pathway is a hypothesis; a clinical outcome trial is the answer. This article maps all eleven pathways, shows where each one’s evidence currently sits, and names the recurring reasons a compelling mechanism fails to become a clinical benefit. The skill it builds is translation — turning supplement marketing into the pathway it targets, then asking whether changing that pathway in humans has ever been shown to prevent heart attacks, strokes, or cardiovascular death.

Introduction

Most supplement claims sound credible because they borrow from real biology. The mechanisms on the labels are not invented: atherosclerosis genuinely is an inflammatory disease, CoQ10 genuinely is essential to cardiac energy production, homocysteine genuinely did predict cardiovascular risk in observational studies. The pathways are real — which is precisely what makes them so easy to misuse.

A real biological pathway is a hypothesis, not a conclusion. The pathway can predict that a supplement should help; only a clinical trial shows whether it does. The gap between those two is where most supplement evidence holds up or falls apart, and this article makes that gap visible across all eleven pathways. The skill it teaches is to translate a marketing phrase into the pathway it targets, then ask whether changing that pathway in humans has ever reduced cardiovascular events — a question that applies not only to the supplements in this series but to any cardiovascular claim you encounter.

This is not an argument that the biology is wrong. The biology is usually well-established. The question is what happens when an oral supplement is used to act on that biology in a living human being, and whether the predicted benefit actually appears. Most claims rest on the lower rungs of the evidence hierarchy — biochemistry and biomarkers — presented as though they had reached the top, which is clinical outcomes. The biology stops one step too early, and a hypothesis is dressed as a conclusion.

One carve-out before the pathways: the skepticism here applies to prevention and optimization claims, not to deficiency correction. Documented hypomagnesemia, B12 deficiency, or severe hypokalemia are situations where the biology alone justifies correction, because the intervention addresses a real physiological gap rather than trying to enhance a system already working adequately. Pathway 5 covers that distinction directly.

How the Pathway Map Was Built

The eleven pathways are not a textbook taxonomy of cardiovascular physiology; they are a map of where supplement claims actually live. Each was identified by working backward from the marketing language consumers encounter — “antioxidant support,” “natural blood thinner,” “cardiovascular function” — to the biology being invoked. For each, the same four questions were asked: Is the underlying biology real? Has a supplement targeting it produced biomarker effects in humans? Has a supplement targeting it reduced cardiovascular events in randomized trials? And has the pathway been proven modifiable by any prescription drug — establishing that the target is reachable in principle, even if supplements have not reached it?

The method is the one Article 1 introduced: clinical events are the standard, biomarkers are hypothesis-generating, mechanism alone is not proof. The eleven pathways are eleven applications of that single framework, which is why a reader who applies it to a supplement not covered here — including one that does not exist yet — should reach an equally specific conclusion. The framework is the constant; only the evidence changes.

How to Use This Article

The eleven pathways are a tool, not a list to memorize. Three steps apply them to any claim you encounter.

Step 1 — Translate the marketing into a pathway. “Supports cardiovascular health,” “promotes circulation,” “natural ACE inhibitor” — each invokes one of the eleven pathways below. Naming the pathway sharpens the question from “does this work?” to “has changing this pathway in humans ever been shown to reduce cardiovascular events?”

Step 2 — Find where the evidence sits. For the named pathway, locate its evidence on the Outcomes Ladder. Is there only mechanistic plausibility? Biomarker changes in human studies? An actual clinical outcome trial? That tells you what kind of claim the supplement is really making, regardless of how the label phrases it.

Step 3 — Apply the three Decision Rule questions. Does the evidence show a change in a marker, or a change in clinical outcomes? Is this correcting a documented deficiency, or claiming to optimize an already-functioning system? Does this category carry interaction or safety risk that requires a prescriber conversation?

That is the entire framework. The pathways supply the evidence; the Decision Rule at the end supplies the questions.

Translating Marketing Into Mechanism

Most supplement claims stay vague until you translate them into the pathway they target. The table below does that translation. Each phrase on the left is a biological hypothesis; the question the label never answers is whether that hypothesis has been tested in humans and found to reduce the outcomes that matter.

The Outcomes Ladder

One framework does most of the analytical work in this article. Evidence in cardiovascular medicine runs along a hierarchy of four rungs:

1. Biochemistry — Does it do something measurable in a test tube or cell culture?
2. Physiology — Does it produce an acute, short-lived functional response in humans — a single dose nudging blood flow or relaxing a vessel for a few hours?
3. Markers — Does it produce a sustained change in a standing risk marker — LDL, resting blood pressure, CRP, or blood sugar held down over weeks and months?
4. Clinical events — Does it prevent heart attacks, strokes, cardiovascular death, or heart failure hospitalization?

Most supplement marketing stops at markers and speaks as though it has reached clinical events. The gap between those two rungs is where most of the confusion lives, and most of the money is spent.

A worked example: vitamin E. The biochemistry was clear — vitamin E is a potent antioxidant in laboratory studies, and oxidized LDL drives atherosclerosis. (1) The hypothesis seemed sound: neutralize the oxidative damage and reduce the disease. Then the randomized trials arrived. Across large trials, vitamin E did not reduce heart attacks or strokes (3); a meta-analysis of nearly 136,000 participants found that high doses (≥400 IU/day) increased all-cause mortality. (28) The lower rungs of the ladder supported the hypothesis; the top rung, clinical events, did not. That is the Outcomes Ladder problem in a single example — the foundational story Article 1 examined.

There is a recurring structural reason the gap exists. The relevant biology in cardiovascular disease often unfolds deep within arterial walls, in specific cell types, over decades — not in the circulating blood where a supplement’s effect is easiest to measure. An oral supplement that changes a blood marker has not shown that it is reaching the right place, in the right cells, at the right time. Biological systems also adapt: change one pathway and parallel systems often compensate, which is why improving a number so frequently fails to improve an outcome. The recurring mistake, in short, is treating movement at one rung of this ladder as proof of benefit at the rung above. That distinction appears in every pathway that follows.

The Eleven Pathways at a Glance

The table shows where the evidence sits for each pathway, whether the pathway has proven drug-modifiable in cardiovascular outcomes, and where the gap between supplement claim and clinical proof appears.

The pathways are not equal in evidence — some have more rigorous trial data, some have genuine clinical signals in specific populations — but all eleven follow the same structural pattern: the mechanism is real, the marketing borrows from it, and the clinical outcomes for supplements rarely follow at the level the marketing implies. One more pattern stands out: where a pathway has a successful prescription drug, the contrast with the supplement targeting the same pathway is often dramatic. The pathways work. The supplement-strength interventions targeting them generally don’t.

Pathway 1: Oxidative Stress and Inflammation

The claim. Atherosclerosis — plaque buildup in arteries — is not simply a cholesterol deposit; it is an inflammatory disease of the arterial wall. (1) When LDL particles lodge in artery walls, immune cells try to clean them up, and the chronic inflammation that follows builds plaque over decades that can rupture without warning, triggering most heart attacks. Reactive oxygen species — highly reactive molecules produced as byproducts of normal metabolism — drive part of that damage when chronically dysregulated inside vessel walls. (1) Vitamins C and E, polyphenols, curcumin, green tea extracts, and mixed antioxidant blends claim to neutralize free radicals and reduce inflammation, implying protection against the process driving most heart attacks.

What the evidence shows. Broad antioxidant supplementation has repeatedly failed to reduce cardiovascular events, and at high doses it has caused harm. A large meta-analysis found no convincing evidence that antioxidant vitamin supplements prevent major cardiovascular outcomes. (2) As Article 1 examined, the HOPE trial found no reduction in events with vitamin E in high-risk patients (3); high-dose vitamin E was subsequently associated with increased all-cause mortality (28), and the HOPE-TOO extension found increased heart failure. (29) Beta-carotene was worse. It looked strongly protective in observational studies, so two large trials tested it in people at high risk for lung cancer — and both were stopped early for harm. In CARET, beta-carotene plus vitamin A in 18,314 smokers and asbestos-exposed adults produced a 28% higher incidence of lung cancer, 17% higher overall mortality, and higher cardiovascular mortality (31); the ATBC trial in male smokers found a similar excess. (30) Part of the likely explanation is dose: at the supra-physiologic concentrations supplements create — far above anything food delivers — an antioxidant can behave as a pro-oxidant, and the protection seen at dietary levels does not carry over.

But the inflammation pathway itself is real and modifiable with the right intervention, as two trials showed — though neither is the clean victory a label would imply. CANTOS tested canakinumab, a precision injectable drug that blocks one specific inflammatory protein, interleukin-1 beta. (Cytokines like interleukin-1 beta are signaling proteins immune cells use to communicate.) In patients with prior heart attack and elevated inflammatory markers, canakinumab reduced recurrent cardiovascular events compared with placebo (4) — proof that inflammation is a modifiable driver of disease, not merely a bystander marker. Even so, it did not reduce all-cause mortality, it caused a meaningful increase in fatal infection, and its manufacturer ultimately chose not to pursue a cardiovascular indication. (4) LoDoCo2 went further, testing low-dose colchicine — an inexpensive century-old oral anti-inflammatory — in 5,522 patients with chronic coronary disease; over a median of 29 months, colchicine cut cardiovascular events by 31%. (24) Yet it carried its own caveat the headline number hides: non-cardiovascular deaths were numerically higher in the colchicine group. (24)

The lesson is not that anti-inflammatory supplements protect the heart. It is that highly targeted suppression of specific inflammatory pathways, in carefully selected patients, with potent pharmaceutical agents — and even then with real trade-offs — can reduce events. (4,24) A curcumin capsule is not canakinumab, and it isn’t colchicine either. The specificity, potency, and oversight that made the prescription effects possible are exactly what supplements in this category do not replicate.

Evidence verdict. Mechanistic plausibility strong. CANTOS (4) and LoDoCo2 (24) confirmed inflammation as a modifiable cardiovascular target with prescription drugs, though both carried safety trade-offs. Broad antioxidant and anti-inflammatory supplementation has not replicated those effects, and high doses have caused documented harm — increased mortality and heart failure with vitamin E (28,29), and increased lung cancer and mortality with beta-carotene in smokers. (30,31)

Pathway 2: LDL and Lipid Metabolism

The claim. The relationship between LDL cholesterol and atherosclerotic cardiovascular disease is among the most consistent findings in medicine, supported by genetics, epidemiology, and decades of trials. (5) LDL particles carry cholesterol through the bloodstream, lodge in artery walls, and drive plaque formation; reducing LDL burden reduces that process. Plant sterols and stanols, soluble fiber, and red yeast rice all claim to lower LDL and thereby reduce cardiovascular risk.

The pathway is the most successfully drugged in cardiovascular medicine. The Cholesterol Treatment Trialists’ Collaboration pooled over 170,000 patients across 26 statin trials and demonstrated reductions in major vascular events proportional to the degree of LDL lowering. (27) Ezetimibe (which blocks intestinal cholesterol absorption) and PCSK9 inhibitors (which let the liver clear more LDL) add further benefit on top of statins. The pathway works; the drugs work.

What the evidence shows for supplements. Plant sterols and stanols reduce LDL by roughly 10% in randomized trials, an effect consistent enough to earn FDA-authorized health claims. (6) That LDL reduction is real. What has not been demonstrated in randomized trials is whether it translates into fewer cardiovascular events — the FDA authorization rests on the established causal relationship between LDL and atherosclerosis, not on outcome trials of the supplements themselves. A 10% LDL reduction from a statin carries decades of outcome data (27); a 10% reduction from a supplement does not. These are not equivalent claims.

Soluble fiber — psyllium, oat beta-glucan — lowers LDL by binding bile acids in the gut. (Bile acids are made by the liver from cholesterol to digest dietary fat; when fiber binds and removes them, the liver pulls more cholesterol from the blood to make replacements, and LDL drops.) The mechanism is well-established and the effect consistent. Fiber also carries broader metabolic and dietary benefits, occupying a different category — less a supplement than a dietary component with genuine cardiovascular rationale.

Red yeast rice is a different matter. It contains monacolin K, chemically identical to lovastatin, a prescription statin. It can genuinely lower LDL — and produce genuine statin side effects: muscle toxicity, liver effects, drug interactions. “Natural” does not mean safer or gentler; it means drug-like effects delivered without standardized dosing, mandatory quality control, or the monitoring prescription statins require. The FDA has issued warning letters against red yeast rice products containing significant amounts of monacolin K on the grounds that they constitute an unapproved drug. (7) This is a supplement that deserves to be evaluated as a medication, because pharmacologically it is one.

Evidence verdict. The LDL pathway is causally established (5) and successfully drugged. (27) Biomarker effects are real for plant sterols (6) and fiber. Outcome evidence for supplements in this category has not been established. Red yeast rice carries drug-level risks without drug-level oversight. (7)

Pathway 3: Endothelial Function and Nitric Oxide

The claim. The endothelium — the single-cell layer lining every blood vessel — actively regulates vascular tone, inflammatory signaling, and clotting tendency. Nitric oxide is its primary signal for vessel relaxation, produced inside endothelial cells by an enzyme called endothelial nitric oxide synthase (eNOS). (An enzyme is a protein that drives a specific chemical reaction — here, converting the amino acid L-arginine into nitric oxide.) Endothelial dysfunction — reduced nitric oxide availability, increased inflammation, impaired vascular response — is an early, measurable feature of cardiovascular disease, often present years before clinical events. (1) L-arginine, L-citrulline, and dietary nitrate sources like beetroot juice claim to restore or enhance nitric oxide production.

The clearest proof the pathway is pharmacologically reachable is nitroglycerin: a patient with angina places a tablet under the tongue and chest pain typically resolves within minutes, because nitroglycerin delivers nitric oxide directly to vessels, dilating them and improving coronary blood flow. That shows the pathway is real and accessible to a properly designed drug. It does not establish that long-term nitrate therapy reduces cardiovascular events; chronic dosing has its own complications and outcome benefits remain limited. The supplement strategy — feeding the body more L-arginine raw material so it can make more nitric oxide — has not produced equivalent clinical effects. By the time someone has cardiovascular disease, the eNOS enzyme that converts L-arginine to nitric oxide is often dysfunctional, and more raw material does not fix a broken machine.

What the evidence shows. Dietary nitrate approaches, including beetroot juice, have shown modest but real blood pressure reductions in randomized trials and meta-analyses, particularly in people with hypertension. (8) L-citrulline raises plasma L-arginine and can augment nitric oxide signaling in short-term human studies, supporting physiological plausibility but not long-term cardiovascular benefit. (9)

L-arginine is the cautionary case. Supplementation has generally disappointed in clinical populations, consistent with eNOS becoming functionally impaired in diseased endothelium. More importantly, the VINTAGE MI trial randomized patients following acute ST-elevation myocardial infarction to L-arginine versus placebo on top of standard post-MI therapy. It was stopped early because of higher mortality in the L-arginine group, and the investigators concluded that L-arginine should not be recommended following acute myocardial infarction. (10) This is a documented harm signal in exactly the population supplement marketing would suggest is most likely to benefit — not a theoretical concern. Across this pathway, the effect sizes are substantially smaller than what antihypertensive medications produce, and long-term outcome data remain limited.

Evidence verdict. Short-term physiological effects are measurable, and dietary nitrate can modestly lower blood pressure in some populations. (8) Long-term cardiovascular outcome evidence remains limited. L-arginine carries a documented harm signal in post-MI patients. (10)

Safety note. Blood pressure effects from these supplements can compound with antihypertensive medications — discuss with your physician before starting any of them if you are on blood pressure treatment. L-arginine is not recommended in the period following a heart attack. (10)

Pathway 4: Cellular Energy and CoQ10

The claim. The heart beats roughly 100,000 times a day. It is the highest energy-consuming organ in the body and depends almost entirely on energy produced inside mitochondria — the small structures within each cell that convert food into ATP, the chemical fuel cells use to do work. CoQ10 (coenzyme Q10) is an essential component of the mitochondrial electron transport chain, the molecular assembly line that does the actual energy conversion; without adequate CoQ10, the chain runs less efficiently. Statins reduce circulating CoQ10 as a direct biochemical side effect — the enzyme they block to lower cholesterol also feeds CoQ10 production. (25) The hypothesis: replacing depleted CoQ10 restores mitochondrial function, reducing muscle symptoms and protecting the heart.

What the evidence shows. The Q-SYMBIO trial randomized 420 patients with moderate to severe chronic heart failure to CoQ10 100 mg three times daily or placebo, on top of standard therapy, over two years. CoQ10 reduced major adverse cardiovascular events by roughly half (HR 0.50; 95% CI 0.32–0.80). All-cause mortality was reduced as a secondary endpoint (HR 0.51; 95% CI 0.27–0.95), with wide confidence intervals that warrant caution in interpreting that result, and heart failure symptoms also improved. (11) That is a meaningful signal in a clinical context where cardiac energy metabolism is demonstrably impaired and baseline risk is high.

Q-SYMBIO is the best evidence CoQ10 has in cardiovascular medicine. It is also a single, relatively small trial (420 patients) whose result has not been independently replicated, conducted largely before the newest heart-failure therapies became standard — so it is not definitive, and it does not establish broad preventive benefit. Heart failure patients with impaired cardiac function are a fundamentally different population from otherwise healthy statin users or people buying CoQ10 for general protection, and no large independent trial has established outcome benefit in primary prevention.

The statin-CoQ10 connection deserves particular honesty. Statins do measurably reduce circulating CoQ10. (25) Whether that reduction causes the muscle symptoms some statin users experience remains genuinely uncertain, and randomized trials have not consistently shown that CoQ10 supplementation reduces statin-associated muscle symptoms compared with placebo. (12) This is an area where the biology is plausible, the patient experience feels compelling, and the controlled trial data has not confirmed the mechanism.

Evidence verdict. Mechanistic plausibility strong. Genuine clinical signal in documented heart failure (11), with the all-cause mortality result a secondary endpoint carrying wide confidence intervals. Broad preventive benefit not established. Statin-myalgia indication not confirmed in randomized trials. (12)

The next three pathways — electrolytes, homocysteine, and platelets — each illustrate a different version of the same failure mode: an intervention that reliably changes a number without reliably changing the disease.

Pathway 5: Magnesium, Potassium, and Electrolyte Balance

The claim. Magnesium and potassium are essential minerals required for blood pressure regulation, cardiac rhythm, vascular smooth muscle function, and hundreds of enzymatic reactions. (Vascular smooth muscle is the muscle layer in artery walls that contracts and relaxes to regulate vessel diameter; cardiac rhythm depends on precise electrical signals that depend on electrolyte balance, which is why severe potassium or magnesium abnormalities can cause arrhythmias.) Both minerals are commonly found to be suboptimal in clinical populations. (13)

What the evidence shows. This pathway behaves differently from most in this article — not because the biology is wrong, but because deficiency correction is not the same as optimizing a system already functioning adequately. Magnesium deficiency is associated with hypertension and other cardiovascular risks (13), and supplementation has shown blood pressure effects in people with documented deficiency; the effect is smaller or absent in people with normal levels. The clinically relevant question before supplementing is not “will this help my heart?” but “am I actually deficient?” — and that requires a blood test, not a label claim. Dietary potassium has consistent blood pressure evidence, with food sources generally preferred because potassium supplement dosing carries real safety risk; here too, the strongest rationale is deficiency correction, not optimization.

This is where the deficiency carve-out from the introduction applies most directly. Documented hypomagnesemia, symptomatic hypokalemia, or severe electrolyte abnormality — particularly in patients with arrhythmia risk — are situations where the biology alone justifies correction. The skepticism in this article is directed at routine supplementation in people with normal levels, not at correcting a documented gap.

Evidence verdict. Deficiency is clinically relevant. (13) Correcting documented deficiency is more evidence-based than routine supplementation in people with normal levels. Outcome evidence is not established for supplementation in non-deficient populations.

Safety flags. Potassium supplementation can be dangerous in kidney disease or with ACE inhibitors, ARBs, or potassium-sparing diuretics — combinations that can cause life-threatening hyperkalemia (dangerously high potassium that disrupts the heart’s electrical rhythm). High-dose magnesium carries toxicity risk in renal impairment (reduced kidney function affects the body’s ability to clear excess magnesium) and causes gastrointestinal effects at lower doses. These are not supplements to self-prescribe without knowing your baseline levels and kidney function.

Pathway 6: Homocysteine and B Vitamins

The claim. Homocysteine is an amino acid produced when the body breaks down certain proteins. In observational studies, people with higher homocysteine had more heart attacks and strokes, and the biological logic was straightforward: high homocysteine appears to damage the endothelium and promote clotting. B vitamins — folate, B6, and B12 — reliably lower homocysteine. The hypothesis wrote itself: if high homocysteine predicts heart attacks, and B vitamins lower homocysteine, then B vitamins should prevent heart attacks.

What the evidence shows. In HOPE-2, folic acid plus vitamins B6 and B12 reliably lowered homocysteine in 5,522 patients with established vascular disease and did not reduce major cardiovascular events. (14) In NORVIT, B-vitamin treatment after myocardial infarction also failed to reduce recurrent events, with some analyses raising signals of possible harm from certain combinations. (15)

This is the most instructive example in the series of why a measurable marker is not automatically a modifiable cause. Homocysteine rises in conditions that also independently drive cardiovascular disease; lowering the number did not change the underlying biology producing both the elevated homocysteine and the risk. The lab value moved exactly as predicted. The disease did not respond. The homocysteine story is not an anomaly — it is a warning about a category of reasoning that recurs throughout supplement marketing, and a direct illustration of why moving a marker up a rung is not the same as moving clinical outcomes.

Evidence verdict. Biomarker effect reliable and well-replicated. (14,15) Outcome evidence not established. The archetypal example of a marker that correlates with risk without being a cause of it.

Pathway 7: Platelet and Coagulation Pathways

The claim. Arterial clots are what actually cause most heart attacks and strokes. (Platelets are tiny cell fragments that clump together to plug damaged vessels — useful when you cut yourself, dangerous when they form clots inside arteries.) The final event in most acute coronary syndromes (the spectrum from unstable angina to full heart attack) is not the plaque itself but plaque rupture triggering clot formation that occludes the vessel. Some supplements claim antiplatelet or anticoagulant effects: high-dose fish oil, garlic, ginkgo, and nattokinase each market themselves on this mechanism. (16)

Like the LDL pathway, this is one of cardiology’s most successfully drugged. Aspirin, clopidogrel, the newer P2Y12 inhibitors, warfarin, and the direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) collectively reduce heart attacks, strokes, and deaths in trials involving hundreds of thousands of patients. They also cause bleeding, which is why they are prescribed and monitored by physicians.

What the evidence shows for supplements. Some demonstrate measurable effects on clotting parameters in short-term studies. (16) Measurable antiplatelet effects on a laboratory test do not automatically translate into fewer heart attacks or strokes — and they do introduce real bleeding risk, particularly in patients already on antiplatelet or anticoagulant therapy. This is the pathway where the safety concern is most clinically immediate. A supplement with antiplatelet effects added to warfarin, aspirin, or a P2Y12 inhibitor (the class that includes clopidogrel and ticagrelor) creates additive bleeding risk without the established benefit that justifies those medications. A patient on dual antiplatelet therapy after a coronary stent who adds high-dose fish oil, garlic, and ginkgo without telling their cardiologist has stacked multiple agents with potential antiplatelet effects that no one on the care team knows about — a situation that occurs regularly, because patients do not perceive supplements as medications and are rarely asked about them specifically.

Evidence verdict. Measurable clotting effects in some short-term studies. (16) Clinical cardiovascular benefit not established. Bleeding risk and interaction with prescribed antiplatelet or anticoagulant medications is clinically significant and widely underappreciated. If you take any antiplatelet or anticoagulant medication, discuss every supplement in this category with your prescriber before taking it.

Pathway 8: Blood Sugar and Metabolic Signaling

The claim. Insulin resistance — when cells stop responding properly to insulin’s signal to take in blood sugar — is central to type 2 diabetes and substantially increases cardiovascular risk through harmful cholesterol patterns, arterial inflammation, endothelial damage, and accelerated atherosclerosis. (17) Berberine, chromium, and cinnamon claim to improve insulin sensitivity and metabolic markers.

This pathway also has prescription drugs with proven cardiovascular outcome benefit. Metformin has decades of safety and outcome data, and more recently GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated cardiovascular benefit in major outcome trials — among the most important advances in cardiovascular medicine of the past decade.

What the evidence shows for supplements. Berberine is the most pharmacologically active compound in this category; meta-analyses of randomized trials show meaningful improvements in glycemic and lipid markers in studied populations. (17) The effects are real enough that berberine is sometimes compared to metformin — a comparison that should prompt caution rather than enthusiasm, because it means berberine is behaving like a drug, with drug-like interaction potential. It may interact with prescription medications including statins, antidiabetic drugs, and anticoagulants, which is precisely why it should not be treated as a benign add-on; it deserves the same clinical conversation any new medication would prompt. (17) Chromium and cinnamon have smaller, less consistent evidence — some trials show modest glycemic improvements, others none — and cardiovascular outcome data for either do not exist.

Evidence verdict. Berberine — biomarker effects real, interaction risk clinically significant, outcome evidence not established. (17) Chromium and cinnamon — weak and inconsistent evidence.

Pathway 9: The Gut–Heart Axis

The next three pathways are presented more briefly, and that reflects the evidence: the biology is real and actively researched, but the clinical trial base is thin, the human data limited, and the marketing has outrun the science. Section length tracks where the evidence currently sits.

The claim. The microbiome — the trillions of gut bacteria that digest fiber, make vitamins, and produce metabolites that travel through the bloodstream — influences inflammation, lipid metabolism, and vascular function through multiple pathways. (18) Gut microbes metabolize dietary compounds into metabolites including trimethylamine-N-oxide (TMAO), produced when bacteria process certain nutrients found in red meat, eggs, and fish, that have been associated with cardiovascular risk in observational studies. (19) Probiotic and prebiotic supplements claim to optimize this relationship.

What the evidence shows. The biology is actively researched and the questions are genuinely interesting; the leap from interesting biology to cardiovascular protection is where the evidence does not yet reach. TMAO associations with cardiovascular risk come from observational studies, with all the confounding those carry. (19) The microbiome varies enormously between individuals, making generalizations about what any probiotic will produce in a given person hard to support, and cardiovascular outcome benefit from probiotic or prebiotic supplementation has not been established in randomized trials. This is one of the easiest areas for sophisticated-sounding claims to outrun the evidence, because the science is real and the causal story sounds plausible. Plausibility is not proof. This is an area to watch, not one to act on for cardiovascular protection.

Evidence verdict. Signal exists in observational data. (18,19) Causal pathway plausible. Clinical translation through supplement intervention has not followed.

Pathway 10: The Renin-Angiotensin System and “Natural ACE Inhibitors”

The claim. ACE inhibitors and ARBs block the renin-angiotensin-aldosterone system, the body’s primary hormonal blood pressure control network. (When blood pressure drops, the kidneys release renin; renin triggers angiotensin, a powerful vessel constrictor; angiotensin also triggers aldosterone, which makes the kidneys retain salt and water — all raising blood pressure. ACE inhibitors and ARBs interrupt this cascade at different points.) These drugs are among the most robustly proven interventions in cardiovascular medicine, reducing events in high-risk populations, preventing kidney damage in diabetic patients, and reducing mortality in heart failure. (20) Some supplements — certain peptides from fermented foods, specific herbal compounds — claim ACE-inhibiting or renin-angiotensin-modulating effects.

This is one of cardiology’s most successfully drugged pathways. Trials of ACE inhibitors and ARBs across hypertension, heart failure, and post-myocardial infarction have consistently reduced cardiovascular events (20), and the newer angiotensin receptor neprilysin inhibitor (ARNI) class extended these benefits further in heart failure with reduced ejection fraction. The pathway works, the drugs work, and the effect sizes are large enough to substantially change outcomes.

What the evidence shows for supplements. Some compounds do reduce ACE enzyme activity in the laboratory, or produce modest blood pressure reductions in small trials. The problem is the scale of effect: blood pressure reductions in supplement studies are typically 2–5 mmHg systolic, against roughly 10 mmHg or more with prescription ACE inhibitors at standard doses. Lactotripeptides derived from fermented milk have been studied for blood pressure; meta-analyses show small reductions in some populations, but results are inconsistent across trials and ethnically diverse populations, and no outcome data exist. (21) The biology is coherent; the clinical effect is a fraction of what the prescription medications these supplements implicitly reference are known to produce. Calling something a “natural ACE inhibitor” borrows the outcome credibility of drugs with extensive trial evidence and applies it to compounds with modest biomarker effects and no outcome evidence — the label doing clinical work the science has not earned.

Evidence verdict. Small blood pressure effects in some studies. (21) Effect sizes substantially below prescription equivalents. (20) Outcome evidence for supplements not established.

Pathway 11: Vascular Calcification and Vitamin K2

The claim. Arterial calcification (calcium hardening into bone-like deposits where it shouldn’t be, including in artery walls) is not simply calcium depositing passively; it is a regulated biological process involving inhibitory proteins that normally prevent inappropriate calcification. Matrix Gla Protein (MGP) is one such inhibitor, and it requires vitamin K to function: vitamin K activates the protein through a chemical step that lets it bind free calcium and keep it out of artery walls. (22) Vitamin K2, particularly menaquinone-7, is the form most active for this purpose. The hypothesis: supplementing K2 keeps MGP active, slows arterial calcification, and reduces cardiovascular risk.

What the evidence shows. The biology is mechanistically coherent; the clinical evidence has not matched it. In a double-blind randomized trial in older men with aortic valve calcification, menaquinone-7 combined with vitamin D did not reduce aortic valve calcification progression — the primary endpoint — over two years compared with placebo. (22) This is the highest-quality trial directly testing the core marketing claim. A separate follow-up analysis from the same trial population, examining coronary artery calcification, suggested a possible effect, which the investigators themselves characterized as hypothesis-generating rather than definitive. (23) Older observational data showing associations between K2 intake and cardiovascular outcomes carry the healthy-diet confounding that has repeatedly misled in this field.

This does not mean future trials will find no benefit. The biology remains interesting. It means the current evidence does not support the confident claims on K2 supplement labels.

Evidence verdict. Biological rationale legitimate. (22) The best available randomized trial found no reduction in aortic valve calcification progression. (22) Outcome evidence not established.

The Unifying Pattern

Across all eleven pathways, the problem is almost never fabricated biology. The mechanisms are usually real. What fails is the assumption that a real mechanism predicts a useful clinical outcome. The most common reasons it fails repeat so reliably that recognizing them is itself a diagnostic tool.

Biological compensation. The body is a network with feedback loops, not a machine with independent levers, so pushing one pathway often yields less than the biology predicts. Niacin illustrates it: added to statin therapy, it improved the entire lipid panel — raising HDL, lowering LDL and triglycerides — yet produced no benefit and increased serious harm. (26) Moving several markers in the right direction was not the same as moving the disease.

Wrong intervention point. The problem is often a broken or dysfunctional system, not a shortage of raw materials, and adding substrate to a damaged enzyme does not restore the enzyme. L-arginine disappoints in cardiovascular disease because eNOS is functionally impaired in diseased endothelium. (10) CoQ10 helps in documented heart failure but has not proven useful in primary prevention, where the underlying machinery is intact — the same logic in reverse. (11)

Marker is not cause. The lab value improves; the disease does not. Homocysteine is the clearest example: B vitamins reliably lowered the marker, and cardiovascular events were unaffected. (14,15) The same pattern holds for several antioxidant interventions.

Product variability. The active exposure in the body may be too low, too inconsistent, or chemically different from what was studied — which is why Article 2 treats the product question as a separate problem from the evidence question.

Correlation mistaken for causation. Some pathways are markers of disease severity that rise because disease is present; lowering the marker does not address the disease producing it. Observational data cannot distinguish the two, which is why promising associations followed by disappointing trials keep recurring.

There is a sixth pattern worth naming explicitly, because it carries the highest stakes for cardiovascular patients: the same biology that fails to deliver benefit can deliver harm. High-dose vitamin E increased all-cause mortality (28) and, in the HOPE-TOO extension, heart failure (29); beta-carotene increased lung cancer and total mortality in smokers, in two trials stopped early for harm. (30,31) L-arginine after acute MI was stopped early for higher mortality. (10) Niacin increased diabetes, infections, bleeding, and muscle problems while failing to reduce cardiovascular events. (26) High-dose magnesium and potassium can produce serious toxicity in renal impairment, and potassium combined with ACE inhibitors, ARBs, or potassium-sparing diuretics carries genuine risk of life-threatening hyperkalemia. Antiplatelet supplements compound bleeding risk with prescribed anticoagulant and antiplatelet medications. (16) Berberine has clinically meaningful interactions with statins, antidiabetic drugs, and anticoagulants. (17) These are not isolated rare events; they are documented in published trials, in the populations supplement marketing would suggest are most likely to benefit. “Natural” and “supports cardiovascular health” do not preclude harm — and the absence of pre-market cardiovascular safety testing for supplements (Article 2) is precisely why these signals tend to emerge only after products are widely used.

Cardiovascular disease develops over decades through the interaction of genetics, behavior, metabolism, and environment. Altering one biochemical pathway with an oral supplement rarely overrides that complexity, even when the pathway is real and the biology well understood. The closer the evidence gets to real clinical outcomes, the fewer supplement claims remain standing.

The Framework in Action: One Patient, Several Pathways

The clearest way to see the framework working is to walk a single patient through several pathways at once. Consider a composite case — not a specific patient — built from the populations in the trials this article reviews.

A 62-year-old woman with mild hypertension (managed on lisinopril) and elevated LDL cholesterol (her physician has discussed but not yet prescribed a statin). She exercises, sleeps well, and is broadly health-conscious. She walks into a supplement store with a list she found online — CoQ10, beetroot juice extract, plant sterols, vitamin K2, and a “natural ACE inhibitor” peptide — and the clerk recommends all of them. She wants to know which, if any, are worth her money.

CoQ10 (Pathway 4). She has no heart failure and is not yet on a statin. Q-SYMBIO’s positive result was in moderate-to-severe heart failure on optimal therapy (11), a population she does not match. The biology is real; her clinical profile does not place her where the evidence exists.

Beetroot juice extract (Pathway 3). Dietary nitrate has produced modest blood pressure reductions in hypertensive patients (8), but she is already on an ACE inhibitor. Adding a supplement with blood pressure effects to an antihypertensive introduces a variable her physician cannot account for. The conversation belongs with her physician, not the clerk.

Plant sterols (Pathway 2). Plant sterols reduce LDL by roughly 10% in randomized trials (6), and that biomarker effect is real. Whether it reduces cardiovascular events has not been demonstrated in supplement trials. If her physician is weighing a statin, plant sterols are not equivalent: a 10% reduction from a supplement does not carry the outcome evidence a 10% reduction from a statin does. (27)

Vitamin K2 (Pathway 11). The biology is mechanistically interesting, but the best randomized trial directly testing the marketing claim was negative for its primary endpoint. (22) The evidence does not currently support the confident claims on the label.

“Natural ACE inhibitor” peptide (Pathway 10). She is already on a prescription ACE inhibitor with established outcome data. (20) The supplement claims to do something her medication already does, at a fraction of the effect size, with no outcome evidence — borrowing the credibility of her prescription drug to make a claim the supplement evidence has not earned.

The framework does not produce a single answer for this patient. It produces five specific answers, each grounded in the evidence that exists for that pathway and her clinical profile. That is the article working as a tool: the pathways are not equally promising, the evidence is not equally strong, and the right answer differs across the supplements she is considering.

What Strong Evidence Would Actually Look Like

After eleven pathways, the standard is clear. A supplement making genuine cardiovascular claims would need to show: testing in a population where cardiovascular events occur at meaningful rates; hard clinical endpoints (heart attack, stroke, cardiovascular death, heart failure hospitalization) rather than biomarkers alone; follow-up measured in years rather than weeks; a defined, reproducible product so that what was studied can actually be purchased and taken consistently; and consistency across multiple independent trials run by researchers with no shared financial interest.

Very few supplements have been tested this way; most have not been tested this way at all. This is not because the industry is uniquely corrupt — it is because these trials are large, expensive, and slow, and companies manufacturing supplements rarely have the financial incentive to fund trials that could produce a negative result. That structural reality is part of why the evidence gap exists and why it is unlikely to close quickly. It also means the absence of outcome evidence is not proof of inefficacy. But it is not proof of efficacy either, and in cardiovascular medicine, where the alternatives have strong outcome data, that distinction matters enormously.

The Decision Rule

Most people taking cardiovascular supplements are not making reckless choices. They are health-conscious, engaged with their own wellbeing, and responding to information that sounds genuinely scientific — because it often is. The framework in this article is not a dismissal of that intent; it is a protection of it. The goal is to direct the effort and resources people invest in their cardiovascular health toward things shown to help, and away from things that borrow the language of science without meeting its standard.

A pathway is not proof; a biomarker change is not protection. When evaluating any supplement claim, three questions resolve most decisions:

1. Does the evidence show a change in a marker, or a change in clinical outcomes? If markers only, you are at the third rung of the Outcomes Ladder, not the top — a hypothesis, not a conclusion.
2. Is this correcting a genuine deficiency, or claiming to optimize a system that is already working? Deficiency correction is more evidence-based than optimization of a replete system, but it requires knowing your actual levels rather than assuming the supplement fills a gap.
3. Does this category carry known interaction or safety risk? Pathways 3, 7, and 8 in particular — the endothelial pathway after acute MI (10), platelet and coagulation pathways (16), and pharmacologically active metabolic compounds like berberine (17) — carry risks that require a prescriber conversation, not just a label check.

Across the eleven pathways, a few categories hold up better than others. Deficiency correction in populations with documented deficiency, particularly magnesium and potassium, is a different evidence base than optimization in replete populations. (13) Soluble fiber, where the mechanism and clinical rationale genuinely align, occupies a more defensible position than most supplements in this series. CoQ10 in documented heart failure has one trial worth a clinical conversation. (11) Red yeast rice produces real LDL reduction — but precisely because it does, it warrants drug-level oversight rather than self-supplementation. (7)

Other categories are consistently oversold. Broad antioxidant and anti-inflammatory claims have repeatedly failed in randomized trials, sometimes with harm signals. (2,3,28) “Natural blood thinner” marketing in patients on anticoagulant therapy adds bleeding risk without outcome evidence. (16) “Natural ACE inhibitor” language applies the credibility of one of cardiology’s most successful drug classes to compounds with modest biomarker effects and no outcome trials. (21) And any pathway claim resting only on a biomarker change in a small short-term trial is, by definition, a hypothesis marketed as a conclusion.

The Bottom Line

Eleven pathways, eleven versions of the same pattern: the biology is real, the mechanism is borrowed accurately, and the clinical outcomes for supplements have not followed. This is not bad luck in trial design. It is what happens when a single oral supplement is used to alter a pathway in a disease driven by decades of genetics, metabolism, and environment.

The pathways themselves often work — when the right drug, at the right dose, in the right population, is used. CANTOS and LoDoCo2 proved inflammation is modifiable (4,24); statins, ezetimibe, and PCSK9 inhibitors proved LDL is modifiable (27); nitroglycerin shows the nitric oxide pathway is reachable; aspirin and the anticoagulants prove the clotting pathway is modifiable; ACE inhibitors and ARBs prove the renin-angiotensin pathway is modifiable (20); and metformin, GLP-1 agonists, and SGLT2 inhibitors prove the metabolic pathway responds to prescription therapy. What the supplement evidence consistently shows is that mechanism alone — without the dose, specificity, formulation, and clinical context that make prescription drugs work — does not translate into prevention.

The homocysteine story is the clearest warning of the alternative pattern: a real-looking marker, a logical hypothesis, B vitamins that reliably lowered the marker, large well-designed trials, and cardiovascular events completely unaffected. (14,15) That result has repeated across antioxidants and niacin. (3,26)

When a label describes a biological pathway, it is describing a hypothesis, not reporting an outcome. Mechanism is a hypothesis; outcome data is the answer. Most cardiovascular supplements offer only the first, and the framework in this article exists to keep you from confusing them.

Article 4 examines omega-3 fatty acids — the only supplement category in this series with an FDA-approved cardiovascular drug indication, and the precise reason that approval does not extend to most fish oil products on pharmacy shelves.

Key Terms

Atherosclerosis: Plaque buildup in artery walls, the underlying process driving most heart attacks and many strokes. An inflammatory disease as much as a lipid disease.

Biomarker: A measurable indicator of a biological process. Moving a biomarker in the right direction does not guarantee moving outcomes in the right direction, as the homocysteine and niacin stories each demonstrate.

Cytokine: A signaling protein immune cells use to communicate. Interleukin-1 beta is one cytokine targeted by canakinumab in CANTOS.

Endothelium: The single-cell layer lining every blood vessel. Not passive plumbing, but an active regulator of vascular tone, inflammation, and clotting tendency.

eNOS (endothelial nitric oxide synthase): The enzyme inside endothelial cells that converts L-arginine into nitric oxide. Becomes dysfunctional in cardiovascular disease, which is why providing more L-arginine substrate does not reliably restore nitric oxide signaling.

Hyperkalemia: Too much potassium in the blood. The danger is not the number itself but that the heart’s electrical system depends on potassium staying within a narrow range; elevated potassium can cause life-threatening arrhythmias.

LDL cholesterol: The lipoprotein particle that directly contributes to plaque formation when elevated over time. The causal relationship between LDL and atherosclerosis is among the most firmly established in medicine — but LDL reduction through different mechanisms does not carry identical outcome evidence.

Mitochondria: The structures within cells that convert food into ATP, the chemical fuel cells use to do work. Cardiac muscle is highly dependent on mitochondrial function.

Nitric oxide: The endothelium’s primary signaling molecule for vessel relaxation. Deficiency is an early feature of vascular disease; providing more precursor does not reliably restore function in damaged endothelium.

Outcomes Ladder: The hierarchy from biochemistry to physiology to markers to clinical events. Most supplement evidence stops before the top rung, and most marketing presents the lower rungs as though they were the top.

Renin-angiotensin-aldosterone system (RAAS): The body’s primary hormonal blood pressure control system. ACE inhibitors and ARBs interrupt this cascade and are among the most successful drug classes in cardiovascular medicine.

Surrogate endpoint: A measurable marker used in place of a clinical outcome. Surrogate improvements do not reliably predict outcome improvements, as the homocysteine story makes clearest.

TMAO (trimethylamine-N-oxide): A gut microbiome-derived metabolite associated with cardiovascular risk in observational studies. Whether modifying TMAO through diet or supplements reduces cardiovascular events has not been established in intervention trials.

References

1. Förstermann U, Xia N, Li H. Vascular oxidative stress and endothelial dysfunction in atherosclerosis. Circ Res. 2017;120(4):713–735.
2. Myung SK, Ju W, Cho B, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis. BMJ. 2013;346:f10.
3. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):154–160.
4. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
5. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459–2472.
6. Katan MB, Grundy SM, Jones P, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78(8):965–978.
7. US Food and Drug Administration. FDA warns consumers to avoid red yeast rice products promoted on internet as treatments for high cholesterol. FDA Consumer Update. 2007.
8. Benjamim CJR, Porto AA, Valenti VE, et al. Nitrate derived from beetroot juice lowers blood pressure in patients with arterial hypertension: a systematic review and meta-analysis. Front Nutr. 2022;9:823039.
9. Schwedhelm E, Maas R, Freese R, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine. Br J Clin Pharmacol. 2008;65(1):51–59.
10. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295(1):58–64.
11. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO — a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641–649.
12. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329–335.
13. Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutr Rev. 2012;70(3):153–164.
14. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–1577.
15. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578–1588.
16. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286(2):208–216.
17. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81.
18. Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019;16(3):137–154.
19. Tang WHW, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584.
20. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13–e115.
21. Cicero AFG, Aubin F, Azais-Braesco V, Borghi C. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens. 2013;26(3):442–449.
22. Diederichsen ACP, Lindholt JS, Möller S, et al. Vitamin K2 and D in patients with aortic valve calcification: a randomized double-blinded clinical trial. Circulation. 2022;145(18):1387–1397.
23. Hasific S, Øvrehus KA, Lindholt JS, et al. Effects of vitamin K2 and D supplementation on coronary artery disease in men: a randomized controlled trial. JACC Adv. 2023;2(9):100643.
24. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847.
25. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33(3):226–229.
26. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.
27. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
28. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46.
29. Lonn E, Bosch J, Yusuf S, et al; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293(11):1338–1347.
30. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029–1035.
31. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334(18):1150–1155.

HeartBuddi • Your heart. Own it.